12 results about "Leprosy" patented technology

The invention relates to the technical field of leprosy nerve injury grading evaluation, in particular to a leprosy nerve injury intelligent grading evaluation method based on high-frequency ultrasound multi-parameter fusion, which comprises the following steps: acquiring multiple frames of nerve images by adopting high-frequency ultrasound, analyzing a gray scale trend to construct a closed path, and screening out frames with abnormal distribution to generate a consistent sequence; and extracting a region coverage range, a brightness form and a texture arrangement feature, generating a change description according to a feature difference, matching a preset grading rule according to a description type, judging a damage level, and obtaining an intelligent grading evaluation result of the leprosy nerve injury. According to the method, the neural region is adaptively defined by using the image gray scale change, experience dependence is reduced, the consistency image sequence is screened, the spatial homology and stability of feature comparison are ensured, the single index interference is described and weakened based on the overall trend organization change, and the continuity and distinction degree of the evaluation result under the complex background are ensured. And the applicability of the grading conclusion in the dynamic observation scene is enhanced.

This invention provides a compound drug for treating melioidosis, its preparation method, and its application. The drug comprises active components of traditional Chinese medicine, a bioactive preparation, and a pharmaceutically acceptable carrier. The active components of traditional Chinese medicine are primarily extracts of Scutellaria baicalensis, Coptis chinensis, Fagopyrum dibotrys, and Polygonum cuspidatum. The bioactive preparation includes polymyxin B, homoserine lactonease, and recombinant human β-defensin 3. The components work synergistically to construct a comprehensive intervention system covering all pathological stages, including biofilm disruption, sterilization, anti-endotoxin activity, intracellular bacterial clearance, immune regulation, and tissue repair. This system can effectively disrupt bacterial biofilms, kill multidrug-resistant strains, neutralize endotoxins, and eliminate latent intracellular bacteria, addressing the core pain points of existing melioidosis treatments, such as strong drug resistance, significant toxic side effects, and high recurrence rates. The preparation process of this invention is carried out under low-temperature and sterile conditions throughout, which fully preserves the stability of the active ingredients, making it suitable for industrial production. The drug can be prepared in various dosage forms, covering all clinical subtypes of melioidosis, and possesses clinical application value and promising prospects for widespread application.

The invention discloses a method for efficient traceless editing of a myxobacteria genome and application. According to the invention, a TnpB cutting system ISDra2 of deinococcus radiodurans is combined with a homologous recombination system MxRedET of myxobacteria, so that a one-step traceless editing platform (MxDIRECT) is formed. The ISDra2 is responsible for accurately positioning and cutting target DNA, and the MxRedET immediately realizes efficient fragment integration or replacement at a cut, so that operations such as gene knockout, insertion and replacement are realized. According to the method, the editing efficiency of myxobacteria is improved to 100% from original 1%, the period is shortened to 5-7 days from 3-6 months, and one-step double-site traceless editing can be achieved through double-site design. The longest DNA of about 80 kb can be knocked out through a single incision, and the longest DNA can reach 200 kb through double incisions; and mononucleotide replacement can be carried out at any position, so that accurate base editing is realized. The technology provides an efficient and accurate tool for modifying functional genes and metabolic pathways of the myxobacteria chassis cells, and obviously promotes the research of synthetic biology.

The utility model discloses a leprosy patient foot ulcer seepage adsorption insole which comprises a macromolecule water absorption fiber insole body, a medical silica gel insole body is detachably arranged on the macromolecule water absorption fiber insole body, a plurality of seepage flow guide holes are formed in the medical silica gel insole body, and the seepage flow guide holes penetrate through the medical silica gel insole body. The insole has the advantages that wound exudate of a patient flows into the macromolecule water-absorbing fiber insole on the lower layer through the exudate flow guide holes, liquid retention on the surface of the insole is reduced, the wound is kept dry, and comfort is better. The medical silica gel insole is in contact with the foot of the patient, so that the comfort is better, and the pain of the patient is relieved. The detachable design is adopted between the macromolecule water-absorbing fiber insole and the medical silica gel insole, the macromolecule water-absorbing fiber insole can be independently detached after seepage adsorption is saturated, the medical silica gel insole can be repeatedly used after being cleaned and aired, and the long-term use cost is reduced.

The present invention relates to: an isoindolinone derivative compound having a glutarimide mother nucleus in which quinoline is substituted; and application thereof, and, more specifically, to an isoindolinone derivative compound having a glutarimide mother nucleus, in which quinoline is substituted, with a thalidomide analog structure. A compound of chemical formula 1, according to the present invention, specifically binds to a CRBN protein and is involved in functions thereof. Therefore, the compound of the present invention can be effectively used in the prevention or treatment of leprosy, chronic graft versus host disease, inflammatory diseases or cancer, which are caused by activity of the CRBN protein.

The present disclosure provides heterocyclic antibacterial compounds, e.g., 1,4-dihydro-2H-pyrano[3,4-c]quinolone compounds, that are inhibitors of GuaB in mycobacteria. The compounds advantageously inhibit mycobacterial growth and survival, and as such, the compounds are useful to treat infectious disease caused by mycobacteria (e.g., tuberculosis, leprosy, nontuberculous mycobacterial infections, or a combination thereof). Pharmaceutical compositions comprising said compounds are also provided.

The invention discloses a joint detection marker for diagnosis and differential diagnosis of rhinomyelitis and application of the joint detection marker. The marker comprises cell factor E-selectin protein / nucleic acid in a blood sample of an infected patient and an antibody aiming at rhinomyelitis HCP1 protein. The invention creatively provides the combined marker for diagnosing the infection of the rhinotrichum-like disease, and the combined marker can be used for differential diagnosis of the current symptom and the previous infection of the rhinotrichum-like disease. The combined marker also has the potential of being used as a target spot for preventing and treating burkholderia pseudomallei infection.

The application belongs to the field of biological medicine, and particularly relates to a leprosy early diagnosis biomarker, a detection reagent and application thereof. The application provides a leprosy early diagnosis biomarker, which is one or more of CCL2 / MCP-1, IL-8, JAKM, ATP, ND1, SERP, FLJ10489, LINC00659, LOC34487, LOC101928143, MIR22 and NCF1C, 12 genes. The application finds that the differentially expressed genes can be used as useful biomarkers, and provide a good basis for the development of a blood detection method for rapid diagnosis of leprosy.

The present application relates to the technical field of leprosy nerve injury grading evaluation, in particular to a leprosy nerve injury intelligent grading evaluation method based on high-frequency ultrasound multi-parameter fusion, which adopts high-frequency ultrasound to obtain multiple frames of nerve images, analyzes gray scale trends to construct a closed path, screens out abnormal distribution frames to generate a consistent sequence, extracts regional coverage, brightness morphology and texture arrangement features, generates change descriptions by comparing feature differences, matches preset grading rules according to description types, determines the injury level, and obtains the leprosy nerve injury intelligent grading evaluation result. The present application adaptively defines the nerve region by using the gray scale change of the image, reduces the experience dependence, ensures the spatial homology and stability of the feature comparison by screening the consistent image sequence, weakens the single index interference based on the overall trend of the change description, guarantees the coherence and distinguishability of the evaluation result under the complex background, and enhances the applicability of the grading conclusion in the dynamic observation scene.

The present invention relates to an isoindolinone derivative compound having a glutarimide mother nucleus, and an application thereof, and more specifically, to an isoindolinone derivative compound in which a glutarimide mother nucleus is substituted with phenylcyclopropane having a thalidomide analog structure. The compound of chemical formula 1 according to the present invention specifically binds to the CRBN protein and is involved in functions thereof. Thus, the compound of the present invention may be beneficially used in the prevention or treatment of leprosy, chronic graft versus host disease, inflammatory diseases, or cancer caused by actions of the CRBN protein.

The invention discloses a pestilence-removing powder and preparation and application methods thereof, the pestilence-removing powder comprises rhizoma atractylodis, wrinkled gianthyssop herb, dahurian angelica root, fortune eupatorium herb, elsholtzia, folium artemisiae argyi, tsaoko amomum fruit, clove and mint, and the compatibility proportion of the traditional Chinese medicines is determined according to the pharmacological action, interaction and side effect characteristics of the traditional Chinese medicines of different illness states and physiques of users and the symptom, physique and allergy history information of patients. Adaptively adjusting the compatibility proportion of the traditional Chinese medicines; the preparation ratio range of the traditional Chinese medicines is (1.2 to 1.5): (1 to 2): (1.2 to 2): (1.2 to 3): (1.2 to 1.5): (1.2 to 2.7): (1 to 2): (1.2 to 1.35) Atractylodes lancea, agastache rugosus, angelica dahurica, eupatorium, elsholtzia, folium artemisiae argyi, amomum tsao-ko, clove and mint are all traditional Chinese medicine tablets, the traditional Chinese medicine decoction pieces are crushed into coarse powder through a traditional Chinese medicine pulverizer, the coarse powder is prepared into powder, the powder is loaded into a traditional Chinese medicine fumigation patch, and the traditional Chinese medicine fumigation patch is made of a degradable non-woven fabric bag, is pasted to an affected part, an acupuncture point or an external heat source, and is activated by body temperature or the external heat source to release traditional Chinese medicine particles. The traditional Chinese medicine composition has a positive effect in the aspects of epidemic prevention and disease prevention.

This invention discloses a highly efficient and scarless method for editing the genome of myxobacteria and its applications. This invention combines the ISDra2 TnpB cleavage system of *Gastrococcus radiodurans* with the MxRedET homologous recombination system of myxobacteria to form a one-step scarless editing platform (MxDIRECT). ISDra2 is responsible for precisely locating and cleaving the target DNA, and MxRedET then efficiently integrates or replaces fragments at the cleavage site, enabling gene knockout, insertion, and replacement operations. This method increases the editing efficiency of myxobacteria from 1% to 100%, shortens the cycle from 3-6 months to 5-7 days, and allows for one-step two-site scarless editing through a two-site design. A single cleavage can knock out up to approximately 80kb of DNA, while two cleavages can knock out up to 200kb; and single nucleotide substitutions can be performed at any location, achieving precise base editing. This technology provides an efficient and precise tool for modifying the functional genes and metabolic pathways of myxobacterial chassis cells, significantly advancing synthetic biology research.